LTRN Lantern Pharma Inc.
$0.64▲ +2.60%
Healthcare
Other
Volume 71.9K
Avg Volume (10D) 338.6K
Key Metrics & Fundamentals
Market Cap
$9.56M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.59 - 4.34
% vs 50 MA
-54.24%
% vs 200 MA
-74.43%
RSI-14
21.9
MACD Histogram
+0.0400
Beta (1Y vs SPY)
2.75
Free Cash Flow
-$2.94M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.38M
COGS
–
Operating Exp
$3.51M
Operating Income
-$3.51M
EBIT
-$3.51M
Pretax Income
-$7.07M
Net Income
-$7.07M
EPS (Diluted)
-0.57
Price & Volume History
Loading chart…
Recent News
What Could Go Wrong With Recursion Pharmaceuticals Stock?
Trefis · Oct 8, 2026 7:58 PM ET
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
Business Wire · Oct 8, 2026 8:00 AM ET
Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
Clinical Trials Arena · Oct 8, 2026 7:05 AM ET
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Business Wire · Oct 7, 2026 8:31 AM ET
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
Business Wire · Sep 30, 2026 4:01 PM ET
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
Business Wire · Sep 29, 2026 8:00 AM ET
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
ACCESS Newswire · Sep 26, 2026 10:28 AM ET
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Business Wire · Sep 23, 2026 7:45 AM ET
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
Business Wire · Sep 22, 2026 7:45 AM ET
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
ACCESS Newswire · Sep 19, 2026 11:45 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See LTRN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.